PXS announces positive interim data from myelofibrosis trial
19th
Oct 22
Release Date: 19/10/2022 9:06am
- PXS-5505 continues to exhibit an excellent safety profile with encouraging signs of clinical activity in patients’ ineligible for a JAK inhibitor.
- 15 out of 24 patients recruited with full recruitment expected by year end and results in Q3 2023.
Categories: News and Media